VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Illumina, Inc. $ILMN

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 295,711 shares of the life sciences company’s stock, valued at approximately $51,995,000.

A number of other institutional investors have also added to or reduced their stakes in the company. California State Teachers Retirement System increased its stake in Illumina by 16,869.5% in the 2nd quarter. California State Teachers Retirement System now owns 40,144,099 shares of the life sciences company’s stock valued at $7,058,537,000 after buying an additional 39,907,533 shares during the last quarter. Guardian Wealth Advisors LLC NC purchased a new position in shares of Illumina in the 2nd quarter worth approximately $257,000. Wedmont Private Capital boosted its stake in shares of Illumina by 4.7% in the 2nd quarter. Wedmont Private Capital now owns 3,025 shares of the life sciences company’s stock worth $575,000 after buying an additional 135 shares during the last quarter. HB Wealth Management LLC grew its holdings in shares of Illumina by 14.6% in the second quarter. HB Wealth Management LLC now owns 6,062 shares of the life sciences company’s stock valued at $1,066,000 after acquiring an additional 770 shares in the last quarter. Finally, Saudi Central Bank grew its holdings in shares of Illumina by 85.0% in the second quarter. Saudi Central Bank now owns 10,435 shares of the life sciences company’s stock valued at $1,835,000 after acquiring an additional 4,795 shares in the last quarter. 89.42% of the stock is owned by institutional investors.

Illumina Stock Performance

NASDAQ:ILMN opened at $218.22 on Monday. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $231.81. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The firm’s 50 day moving average is $198.42 and its 200 day moving average is $159.33. The stock has a market capitalization of $32.95 billion, a PE ratio of 40.71, a price-to-earnings-growth ratio of 3.09 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the company earned $1.19 earnings per share. Illumina’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ILMN. Royal Bank Of Canada lifted their price target on Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Leerink Partners upped their price objective on Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, July 17th. Guggenheim raised their target price on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Canaccord Genuity Group boosted their price target on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a report on Monday, August 3rd. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $191.31.

Insider Activity at Illumina

In other news, Director Keith Meister sold 457,858 shares of the stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 2,062,465 shares of company stock worth $436,589,802. 2.90% of the stock is owned by corporate insiders.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.